With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
“We postulate that these observations may provide novel opportunities for therapeutic interventions for EGFR driven cancers.” “We postulate that BUB1 helps in the formation and stabilization of EGFR ...
(RTTNews) - Ascletis Pharma Inc. said that China National Medical Products Administration (NMPA) approved the Investigational New Drug (IND) application for the in-house developed oral PD-L1 small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback